Published: May 31, 2022
By: Dr. Joseph Mercola
The U.S. Food and Drug Administration (FDA) amended its emergency use authorization for the Pfizer-BioNTech COVID-19 shot to allow a booster dose for children ages 5 to 11.
The FDA’s “evaluation of safety” for the booster dose in young children was based on a study of only about 400 children, and no meeting was held with the Vaccines and Related Biological Products Advisory Committee.
The booster shot is intended to be given at least five months after the primary two-dose series has been completed, but less than one-third — only 28.8% — of U.S. children in this age group have received the first two doses of this experimental gene therapy.
“[G]iven that these children have the lowest coronavirus vaccination rate of all eligible Americans, [as most parents have wisely avoided giving their child the jab] public health experts are not expecting a rush for the booster,” The New York Times reported, and this is good news since multiple red flags have arisen regarding the use of these shots, particularly among children.
COVID shots’ dismal effectiveness wanes rapidly
Booster shots are typically released because the initial shots aren’t working as planned.
This is certainly the case with COVID-19 shots, which have been found to have dismally low effectiveness rates of 12%, according to research conducted by the New York State Department of Health.
RELATED:
In their rationale for why a booster dose is now needed for children, Dr. Peter Marks, Ph.D., director of the FDA’s Center for Biologics Evaluation and Research, said:
“Since authorizing the vaccine for children down to 5 years of age in October 2021, emerging data suggest that vaccine effectiveness against COVID-19 wanes after the second dose of the vaccine in all authorized populations.”
From Dec. 13, 2021, to Jan. 24, 2022, the New York State Department of Health researchers analyzed outcomes among 852,384 children aged 12 to 17 years, and 365,502 children aged 5 to 11 years, who had received two doses of the shots.
Effectiveness declined rapidly among 5- to 11-year-olds, falling from 68% to just 12%.
Protection against hospitalization also dropped, from 100% to 48%. Among 11-year-olds alone, vaccine effectiveness plunged to 11%.
The lackluster response was blamed on the dosage discrepancies among the age groups, as 5- to 11-year-olds receive two 10-microgram Pfizer shots, while 12- to 17-year-olds receive 30-microgram shots.
A CDC study also found that the effectiveness of two doses of Pfizer’s COVID-19 shots against symptomatic COVID-19 infection “was modest and decreased rapidly” from December 2021 to February 2022.
RELATED:
The study found that two to four weeks after the second dose of Pfizer’s COVID-19 shots, effectiveness was 60.1% among 5- to 11-year-olds. This fell to just 28.9% by month 2.
A similar trend was seen among adolescents aged 12 to 15 years. Vaccine effectiveness two to four weeks after the second dose of the shots was 59.5%, and this fell to 16.6% during month two.
Among adolescents who received a booster dose, effectiveness went back up to 71.1% two to 6.5 weeks later, but it’s not revealed what happened after that.
If data from adults are any indication, the boost in effectiveness from the booster will also be short-lived.
Among adults, within four to five months post-booster, protection against the emergency department and urgent care visits due to COVID-19 decreased to 66%, then fell to just 31% after five months or more post-booster.
Children’s booster trial didn’t test effectiveness
The FDA’s decision to allow a booster dose for children was based on an ongoing Pfizer trial — the same one that it used to authorize the first set of COVID-19 shots in the 5- to 11-year-old age group.
RELATED:
Antibody responses were evaluated in only 67 subjects who received a booster shot seven to nine months after the two-dose primary series of shots. “The antibody level against the SARS-CoV-2 virus one month after the booster dose was increased compared to before the booster dose,” the FDA noted.
However, there is still no data on whether the booster is effective against COVID-19, and whether the effectiveness will quickly wane, as it has with all previous shots.
“In the Pfizer-BioNTech clinical trial, children showed a sixfold increase in antibody levels against the original version of the virus one month after receiving the booster, compared with one month after receiving a second dose …“Laboratory tests of blood samples from a tiny subgroup of 30 children also showed 36 times the level of neutralizing antibodies against the Omicron variant compared with levels after only two doses. The study did not show how long the antibodies last or test effectiveness against Covid-19.”
High, artificially elevated antibodies come at a cost
What’s more, the notion that increasing antibodies equates to disease protection and better health is misguided.
Artificially inflated antibodies signal to your body that you’re always infected, and the resulting immune response could prove to be detrimental to your health.
Your adaptive immune system, specifically, generates antibodies that are used to fight pathogens that your body has previously encountered.
During normal infections, your cellular immune system produces high fever and temporary T-cell elevations, along with elevated antibodies to the infection, gradually dissipate.
Ali Ellebedy, Ph.D., an associate professor of pathology & immunology at Washington University School of Medicine in St. Louis, explained, “It’s normal for antibody levels to go down after acute infection, but they don’t go down to zero; they plateau.”
This is a normal response and isn’t a measure of waning immunity.
Discerning the Mystery is a website dedicated to awakening and educating the people to their true potential of mental, spiritual, emotional, and physical growth. It can be difficult work, but if just one person benefits from these efforts, it is entirely worth it.
If you enjoy what you read here, please give the post a like and share on social media. Also, if you enjoyed this article, please consider leaving a donation.
If you enjoy what you read here, please give the post a like and share on social media. Also, if you enjoyed this article, please consider leaving a donation.
Feel free to send us an email and tell us what you think. If you have any suggestions or subjects you would like to see discussed, please let us know.
Thank you for your support.
No comments:
Post a Comment